Abstract

A long-held tenet in inositol-lipid signaling is that cleavage of membrane phosphoinositides by phospholipase Cβ (PLCβ) isozymes to increase cytosolic Ca2+ in living cells is exclusive to Gq- and Gi-sensitive G protein-coupled receptors (GPCRs). Here we extend this central tenet and show that Gs-GPCRs also partake in inositol-lipid signaling and thereby increase cytosolic Ca2+. By combining CRISPR/Cas9 genome editing to delete Gαs, the adenylyl cyclase isoforms 3 and 6, or the PLCβ1-4 isozymes, with pharmacological and genetic inhibition of Gq and G11, we pin down Gs-derived Gβγ as driver of a PLCβ2/3-mediated cytosolic Ca2+ release module. This module does not require but crosstalks with Gαs-dependent cAMP, demands Gαq to release PLCβ3 autoinhibition, but becomes Gq-independent with mutational disruption of the PLCβ3 autoinhibited state. Our findings uncover the key steps of a previously unappreciated mechanism utilized by mammalian cells to finetune their calcium signaling regulation through Gs-GPCRs.

Gs heterotrimers are considered to be poor providers of free Gβγ subunits. Here, the authors show that—despite this—Gs-derived Gβγ dimers are active transducers of GPCR-initiated Ca2+ signals involving phosphoinositide-based signaling routes.

Details

Title
A molecular mechanism to diversify Ca2+ signaling downstream of Gs protein-coupled receptors
Author
Brands, Julian 1 ; Bravo, Sergi 2   VIAFID ORCID Logo  ; Jürgenliemke, Lars 3   VIAFID ORCID Logo  ; Grätz, Lukas 4   VIAFID ORCID Logo  ; Schihada, Hannes 5 ; Frechen, Fabian 6   VIAFID ORCID Logo  ; Alenfelder, Judith 2   VIAFID ORCID Logo  ; Pfeil, Cy 7 ; Ohse, Paul Georg 2 ; Hiratsuka, Suzune 8 ; Kawakami, Kouki 9   VIAFID ORCID Logo  ; Schmacke, Luna C. 5 ; Heycke, Nina 2 ; Inoue, Asuka 10   VIAFID ORCID Logo  ; König, Gabriele 11 ; Pfeifer, Alexander 12   VIAFID ORCID Logo  ; Wachten, Dagmar 6   VIAFID ORCID Logo  ; Schulte, Gunnar 4   VIAFID ORCID Logo  ; Steinmetzer, Torsten 5 ; Watts, Val J. 13 ; Gomeza, Jesús 2   VIAFID ORCID Logo  ; Simon, Katharina 14 ; Kostenis, Evi 2   VIAFID ORCID Logo 

 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); University of Bonn, Research Training Group 1873, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300) 
 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300) 
 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); University of Bonn, Research Training Group 2873, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300) 
 Karolinska Institutet, Department of Physiology and Pharmacology, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626) 
 Philipps-University Marburg, Department of Pharmaceutical Chemistry, Marburg, Germany (GRID:grid.10253.35) (ISNI:0000 0004 1936 9756) 
 University of Bonn, Institute of Innate Immunity, Medical Faculty, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300) 
 University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); University of Bonn, Research Training Group 1873, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); Vrije Universiteit Amsterdam, Amsterdam Institute for Molecular and Life Sciences (AIMMS), Division of Medicinal Chemistry, Faculty of Science, Amsterdam, Netherlands (GRID:grid.12380.38) (ISNI:0000 0004 1754 9227) 
 Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943) 
 Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); The University of Tokyo, Komaba Institute for Science, Meguro, Japan (GRID:grid.26999.3d) (ISNI:0000 0001 2169 1048) 
10  Tohoku University, Graduate School of Pharmaceutical Sciences, Sendai, Japan (GRID:grid.69566.3a) (ISNI:0000 0001 2248 6943); Kyoto University, Graduate School of Pharmaceutical Sciences, Kyoto, Japan (GRID:grid.258799.8) (ISNI:0000 0004 0372 2033) 
11  University of Bonn, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300) 
12  University of Bonn, Institute of Pharmacology and Toxicology, University Hospital, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300) 
13  Purdue University, Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute of Drug Discovery, West Lafayette, USA (GRID:grid.169077.e) (ISNI:0000 0004 1937 2197) 
14  University of Bonn, Molecular, Cellular and Pharmacobiology Section, Institute for Pharmaceutical Biology, Bonn, Germany (GRID:grid.10388.32) (ISNI:0000 0001 2240 3300); University of Padova, Department of Pharmaceutical and Pharmacological Sciences, Padova, Italy (GRID:grid.5608.b) (ISNI:0000 0004 1757 3470) 
Pages
7684
Publication year
2024
Publication date
2024
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
3100357232
Copyright
© The Author(s) 2024. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.